Navigation Links
Ikaria Introduces Dr. Michael Cooreman as Vice President of Translational Medicine
Date:6/24/2008

Translational Medicine Department Strengthens Research & Development Team

CLINTON, N.J., June 24 /PRNewswire/ -- Ikaria Holdings, Inc., a fully integrated critical care biotherapeutics company, announced that Michael Cooreman, M.D., has been introduced as Vice President of Translational Medicine, reporting to Ralf Rosskamp, M.D., Executive Vice President for Research and Development of Ikaria.

As Vice President of Translational Medicine, Dr. Cooreman is responsible for leading the Company's Translational Medicine Department. Translational Medicine seeks to define as early as possible the indications for which a new compound will most likely show therapeutic benefit, based on the known interaction of the compound in disease pathways, in addition to confirmation of safety and efficacy of that compound in animal studies. Once likely indications are determined, a clinical proof-of-concept study is initiated with the goal of demonstrating clinical safety, pharmacokinetic properties and therapeutic efficacy study in a particular disease. The results are used to make a data-based decision on whether or not to initiate a Phase 3 trial.

Dr. Rosskamp commented, "In this recently created position, Michael will help us translate pre-clinical research findings into meaningful, early clinical trials. Translational Medicine is often defined as 'bench-to-bedside' research and represents a paradigm shift of developing new drugs and devices. Rather than progressing a new drug or device from preclinical research through traditional Phase 1 to 3 development, we will now focus on a much earlier patient-oriented research. This will help Ikaria to accelerate our decision-making process on promising compounds and indications, which we believe will increase our success rate once we enter the costly late stage development phase."

Daniel Tasse, President & CEO of Ikaria, remarked, "Translational Medicine incorporates the use of tools such as biomarkers to bette
'/>"/>

SOURCE Ikaria Holdings, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. New Study Shows Promise for Hydrogen Sulfide in Reducing Heart-Attack Damage, Ikaria Announces
2. Ikaria Founding Scientist Named 2007 MacArthur Fellow
3. Ikaria to Present at 26th Annual JPMorgan Healthcare Conference
4. Ikaria Appoints Daniel Tasse as President and Chief Executive Officer
5. Lota Zoth Elected to Ikaria Board and Named Audit Committee Chair
6. SAFC Expands Hi-Potency API Manufacturing and Introduces Solid-Form Testing at Its Madison Facility
7. Caliper Life Sciences Introduces High Throughput RNA Assay to Improve Workflow in Gene Expression Studies
8. Small Bone Innovations Introduces the Artelon(R) STT Spacer to Increase Treatment Options for Thumb Arthritis
9. Small Bone Innovations Introduces New Distal Radius Plating System to Repair Complex Fractures
10. Advanced Instruments Introduces Worlds Fastest High Throughput Freezing Point Osmometer
11. Harmonex Introduces CliniCom(TM), a Breakthrough in Psychiatric Intake and Assessment Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/23/2015)... 23, 2015  Propanc Health Group Corporation (OTCBB: ... on the development of cancer treatments for patients ... product includes PRP, a patented formulation consisting of ... well as the enzyme amylase designed to synergistically ... combination of anti-cancer agents working in combination with ...
(Date:4/23/2015)... FRANCISCO, CA (PRWEB) April 23, 2015 ... delivery, today announced that the United States Patent and ... the Company’s NANOPOR™ technology. US Pat. ... covers Delpor’s microfabricated drug delivery device for ... Delpor’s proprietary NANOPOR™ technology for the sustained (zero-order) release ...
(Date:4/22/2015)... April 22, 2015 /PRNewswire/ - BioAmber Inc. (NYSE and EURONEXT Paris:BIOA) today announced ... quarter 2015 on Thursday, May 7, 2015 after the ... webcast and conference call for 4.30 pm ET (1.30 ... Live audio of the conference call will be webcast ... members of the news media and the general public. ...
(Date:4/22/2015)... , April 22, 2015 Steep ... analytics, announced today that it has opened an ... continued growth and expansion.  The common stock investment ... Section 506(c), a law intended to encourage funding ... Prior to 506(c), small businesses largely relied on ...
Breaking Biology Technology:Early Stage BioTech offers Plenty of Risk; Propanc Health Group Analyst Brief Issued by BrokerBank Securities, Inc. 2Delpor, Inc. Announces the Issuance of 2 New US Patents Based on its Nanopore Technology which Enables the Sustained Release of Drugs from a Small Implant Device 2Delpor, Inc. Announces the Issuance of 2 New US Patents Based on its Nanopore Technology which Enables the Sustained Release of Drugs from a Small Implant Device 3BioAmber Announces Webcast of Fiscal First Quarter 2015 Financial Results 2Steep Hill Launches $5M Limited Stock Offering 2Steep Hill Launches $5M Limited Stock Offering 3
... Amex: NBS ) ("NeoStem" or the "Company"), an ... today announced that the Company and its wholly-owned subsidiary, Progenitor ... conferences: the 2011 World Stem Cell Summit, the AABB Annual ... 2011 World Stem Cell Summit – ...
... Oct. 4, 2011 Exosome Diagnostics, a leading ... in personalized medicine, today announced the appointment of ... Donovan, M.D., Ph.D., as chief medical officer, and ...  Raphael Bueno, M.D., associate chief of cardiothoracic surgery ...
... have discovered two early-stage phases of carbon nanotube growth ... tangle of tube growth that ultimately yields to orderly ... in the latest edition of the journal Nanotechnology ... Professor of Physics Zhifeng Ren and researcher Dr. Hengzhi ...
Cached Biology Technology:NeoStem Announces Participation in Multiple October Conferences 2NeoStem Announces Participation in Multiple October Conferences 3NeoStem Announces Participation in Multiple October Conferences 4Exosome Diagnostics Announces Additions to Management and Scientific Advisory Board as Company Expands Clinical Validation Studies in Oncology 2Exosome Diagnostics Announces Additions to Management and Scientific Advisory Board as Company Expands Clinical Validation Studies in Oncology 3Exosome Diagnostics Announces Additions to Management and Scientific Advisory Board as Company Expands Clinical Validation Studies in Oncology 4Exosome Diagnostics Announces Additions to Management and Scientific Advisory Board as Company Expands Clinical Validation Studies in Oncology 5Boston College Researchers discover 2 early stages of carbon nanotube growth 2
(Date:3/31/2015)... , March 31, 2015   Guidepoint , a ... of the Post-Surgical Pain Management TRACKER, part of the ... usage trends in the medical device and therapeutics markets. ... data including treatment volumes, market share, and adoption rates ... associated with joint surgery. The Post-Surgical Pain ...
(Date:3/24/2015)... DUBLIN , Mar. 24, 2015 Research and ... addition of the "Global Iris Recognition Market 2015-2019" ... forecast the Global Iris Recognition market to grow at ... This report covers the present scenario and ... for the period 2015-2019. To calculate the market size, ...
(Date:3/24/2015)... PALM BEACH GARDENS, Fla. , March 24, ... of biometric identity management solutions, today announced that ... enabling premium clothing accessory retailer Goorin Bros ... login. The Crossmatch biometrics-based solution secures access to ... customers from the increased risk of data breaches. ...
Breaking Biology News(10 mins):Guidepoint Launches Post-Surgical Pain Management TRACKER 2Guidepoint Launches Post-Surgical Pain Management TRACKER 3Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2Crossmatch Fingerprint Readers Help Retailer Prevent Data Breaches at Point-of-Sale 2
... Cancer Cell describes a small molecule inhibitor of polo-like kinase1 ... cancer therapy. The compound, ON01910, is a potent inhibitor of ... toxicity. The results of this study have led to clinical ... Plk1 is a molecule that plays a key role in ...
... proteins called phosphatases play a key role in the ... fruit flies and mice by researchers at the University ... collaboration with scientists at the Salk Institute, La Jolla, ... stem cells and for silencing expression of neuronal genes ...
... toward understanding the regulation of blood stem cells and ... research study published in the February issue of Developmental ... to examine the role of a key gene known ... from this research will be useful for future studies ...
Cached Biology News:New drug shows promise as powerful anticancer agent 2New insight into regulation of blood stem cells 2
BD BioCoat Collagen IV 150 mm Culture Dishes...
Polymerase (RNA) II (DNA directed) polypeptide L...
Chicken Anti-Human DNA-directed RNA Polymerase II 7.6 Kd Polypeptide (POLR2L Polyclonal AntibodyOther Sub-Family: not assigned-Other Applications: ELISA, Western Blot...
The BD CBA Human Apoptosis Kit can be used to quantitatively measure,cleaved PARP, Bcl-2, and active Caspase-3 protein levels in a single sample. The,Kit performance has been optimized for analysis o...
Biology Products: